Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Go back to Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
(NASDAQ: TLSA) Delayed: 1.16 +0.08 (7.41%)
Previous Close $1.08    52 Week High
Open $1.10    52 Week Low
Day High $1.16    P/E N/A 
Day Low $1.06    EPS
Volume 290,851